Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for multiple myeloma; however, the development of chronic graft-versus-host disease remains a significant challenge. Bronchiolitis obliterans syndrome (BOS) is one of the complications. Even with available medications for treatment, the prognosis of BOS remains poor. We present a 32-year-old female with multiple myeloma experienced BOS 6 months after allo-HSCT. Even with medical treatment, her clinical condition and pulmonary function was deteriorating. Based on the indication of a BODE (Body-mass index, Obstruction, Dyspnoea and Exercise) index of 7, she underwent bilateral lung transplantation 33 months after allo-HSCT. Three months post-operation, there was a significant improvement in pulmonary function. After approximately 5 years of follow-up, her lung function remains stable, and she is able to work and live a normal life. Lung transplantation may be an effective therapeutic strategy for BOS developed after allo-HSCT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893176 | PMC |
| http://dx.doi.org/10.1002/rcr2.70120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: This study aimed to investigate the clinical value of the serum albumin-to-globulin ratio (AGR) in diagnosing multiple myeloma (MM) and its differential diagnosis from other conditions such as liver and kidney diseases to provide scientific evidence for clinical decision-making.
Methods: A total of 52 newly-diagnosed MM patients from Tongxiang First People's Hospital between January 2020 and June 2024 were selected as the study group. Additionally, 56 patients newly diagnosed with liver disease and 58 patients newly diagnosed with kidney disease during the same period were used as disease control groups, along with 54 healthy individuals serving as the normal control group.
In-depth analysis of the safety of CAR-T cell therapy for solid tumors.
Front Immunol
March 2025
Department of Immuno-Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).
View Article and Find Full Text PDFHigh-Risk Nonsecretory Multiple Myeloma With Poor Response to Daratumumab-Based Chemotherapy.
Cureus
February 2025
Internal Medicine, Piedmont Athens Regional, Athens, USA.
Nonsecretory multiple myeloma (NSMM) is the variant of multiple myeloma defined by no detectable M protein secretion in serum or urine electrophoresis. Due to the lack of detectable M spike, diagnosis is often challenging and relies on bone marrow studies. As studies specifically focusing on NSMM are lacking, the current treatment guidelines are based on studies in secretory multiple myeloma.
View Article and Find Full Text PDFMultiple Myeloma Complicated With Bronchiolitis Obliterans Syndrome After Allogeneic Haematopoietic Stem Cell Transplantation and Subsequently Underwent Lung Transplantation Successfully: A Case Report.
Respirol Case Rep
March 2025
Department of Thoracic Medicine Chang Gung Memorial Hospital Taoyuan Taiwan.
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for multiple myeloma; however, the development of chronic graft-versus-host disease remains a significant challenge. Bronchiolitis obliterans syndrome (BOS) is one of the complications. Even with available medications for treatment, the prognosis of BOS remains poor.
View Article and Find Full Text PDFFrom interference to insight: pseudo-lipidemia led to the diagnosis of Waldenström macroglobulinemia.
BMC Cardiovasc Disord
March 2025
Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifu Yuan, Dongcheng District, Beijing, 100730, China.
Waldenström macroglobulinemia (WM) is a rare hematological disorder with an annual incidence of about 3 per million. Its clinical manifestations are diverse and non - specific, and approximately 30% of patients are asymptomatic, making early diagnosis challenging. This paper reports a 73-year-old female who was admitted to the hospital due to atrial fibrillation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!